Your browser doesn't support javascript.
loading
Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Ferguson, Daniel C; McCorkle, J Robert; Barnett, Kelly R; Bonten, Erik J; Bergeron, Brennan P; Bhattarai, Kashi Raj; Yang, Wenjian; Smith, Colton; Hansen, Baranda S; Bajpai, Richa; Dong, Qian; Autry, Robert J; Gocho, Yoshihiro; Diedrich, Jonathan D; Crews, Kristine R; Pruett-Miller, Shondra M; Roberts, Kathryn G; Stock, Wendy; Mullighan, Charles G; Inaba, Hiroto; Jeha, Sima; Pui, Ching-Hon; Yang, Jun J; Relling, Mary V; Evans, William E; Savic, Daniel.
Afiliação
  • Ferguson DC; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • McCorkle JR; Department of Pharmaceutical Sciences.
  • Barnett KR; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Bonten EJ; Department of Pharmaceutical Sciences.
  • Bergeron BP; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Bhattarai KR; Department of Pharmaceutical Sciences.
  • Yang W; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Smith C; Department of Pharmaceutical Sciences.
  • Hansen BS; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Bajpai R; Department of Pharmaceutical Sciences.
  • Dong Q; Graduate School of Biomedical Sciences.
  • Autry RJ; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Gocho Y; Department of Pharmaceutical Sciences.
  • Diedrich JD; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Crews KR; Department of Pharmaceutical Sciences.
  • Pruett-Miller SM; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Roberts KG; Department of Pharmaceutical Sciences.
  • Stock W; Department of Cell and Molecular Biology and Center for Advanced Genome Engineering, and.
  • Mullighan CG; Department of Cell and Molecular Biology and Center for Advanced Genome Engineering, and.
  • Inaba H; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Jeha S; Department of Pharmaceutical Sciences.
  • Pui CH; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Yang JJ; Department of Pharmaceutical Sciences.
  • Relling MV; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
  • Evans WE; Department of Pharmaceutical Sciences.
  • Savic D; Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
Blood Adv ; 6(11): 3386-3397, 2022 06 14.
Article em En | MEDLINE | ID: mdl-35671062
ABSTRACT
Understanding the genomic and epigenetic mechanisms of drug resistance in pediatric acute lymphoblastic leukemia (ALL) is critical for further improvements in treatment outcomes. The role of transcriptomic response in conferring resistance to l-asparaginase (LASP) is poorly understood beyond asparagine synthetase (ASNS). We defined reproducible LASP response genes in LASP-resistant and LASP-sensitive ALL cell lines as well as primary leukemia samples from newly diagnosed patients. Defining target genes of the amino acid stress response-related transcription factor activating transcription factor 4 (ATF4) in ALL cell lines using chromatin immunoprecipitation sequencing (ChIP-seq) revealed 45% of genes that changed expression after LASP treatment were direct targets of the ATF4 transcription factor, and 34% of these genes harbored LASP-responsive ATF4 promoter binding events. SLC7A11 was found to be a response gene in cell lines and patient samples as well as a direct target of ATF4. SLC7A11 was also one of only 2.4% of LASP response genes with basal level gene expression that also correlated with LASP ex vivo resistance in primary leukemia cells. Experiments using chemical inhibition of SLC7A11 with sulfasalazine, gene overexpression, and partial gene knockout recapitulated LASP resistance or sensitivity in ALL cell lines. These findings show the importance of assessing changes in gene expression following treatment with an antileukemic agent for its association with drug resistance and highlight that many response genes may not differ in their basal expression in drug-resistant leukemia cells.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspartato-Amônia Ligase / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Child / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspartato-Amônia Ligase / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Child / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article